Current Document Type: HighlightsVideoPage Adjuvant Osimertinib In Patients With Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer Final Overall Survival Analysis - JADPRO

Watch More Highlights

Lisa Kottschade, APRN, MSN, CNP, FAPO, of the Mayo Clinic, discusses the planned final overall survival analysis from the ADAURA trial. This study randomized eligible patients (stage IB, II, or IIIA NSCLC) to osimertinib 80 mg once daily or placebo until disease recurrence, treatment completion, or a discontinuation criterion was met. ADAURA is the first global phase III study to demonstrate a statistically significant DFS and OS benefit with targeted treatment for patients with EGFRm stage IB to IIIA NSCLC (Abstract LBA3).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.